TY - JOUR
T1 - Methods and techniques for in vitro subcellular localization of radiopharmaceuticals and radionuclides
AU - Costa, Ines M.
AU - Cheng, Jordan
AU - Osytek, Katarzyna M.
AU - Imberti, Cinzia
AU - Terry, Samantha Y.A.
N1 - Funding Information:
I.M.C. would like to acknowledge funding from the EPSRC Centre for Doctoral Training in Medical Imaging [ EP/L015226/1] and National Physical Laboratory . J.C. and K.O. would like to acknowledge funding from the MRC Doctoral Training Partnership in Biomedical Sciences [ MR/N013700/1] . K.O. was also supported by Theragnostics Limited . C.I. was supported by the Wellcome Trust [ 209173/Z/17/Z] . This work was also supported by the Wellcome / EPSRC Centre for Medical Engineering at King's College London [ WT 203148/Z/16/Z ] and by EPSRC Programme Grant [ EP/S032789/1 ].
Funding Information:
I.M.C. would like to acknowledge funding from the EPSRC Centre for Doctoral Training in Medical Imaging [EP/L015226/1] and National Physical Laboratory. J.C. and K.O. would like to acknowledge funding from the MRC Doctoral Training Partnership in Biomedical Sciences [MR/N013700/1]. K.O. was also supported by Theragnostics Limited. C.I. was supported by the Wellcome Trust [209173/Z/17/Z]. This work was also supported by the Wellcome/EPSRC Centre for Medical Engineering at King's College London [WT 203148/Z/16/Z] and by EPSRC Programme Grant [EP/S032789/1]. Finally, authors would like to thank Dr. Melanie Bailey and Dr. Catia Costa from the National Ion Beam Centre [EPSRC funding - NS/A000059/1], Dr. Elizabeth M. Bolitho (University of Warwick), Prof Philip Blower (King's College London), and Dr. Theodora Stewart from the London Metallomics Facility for their help and support while working on this review.
Publisher Copyright:
© 2021 Elsevier Inc.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - In oncology, the holy grail of radiotherapy is specific radiation dose deposition in tumours with minimal healthy tissue toxicity. If used appropriately, injectable, systemic radionuclide therapies could meet these criteria, even for treatment of micrometastases and single circulating tumour cells. The clinical use of α and β− particle-emitting molecular radionuclide therapies is rising, however clinical translation of Auger electron-emitting radionuclides is hampered by uncertainty around their exact subcellular localisation, which in turn affects the accuracy of dosimetry. This review aims to discuss and compare the advantages and disadvantages of various subcellular localisation methods available to localise radiopharmaceuticals and radionuclides for in vitro investigations.
AB - In oncology, the holy grail of radiotherapy is specific radiation dose deposition in tumours with minimal healthy tissue toxicity. If used appropriately, injectable, systemic radionuclide therapies could meet these criteria, even for treatment of micrometastases and single circulating tumour cells. The clinical use of α and β− particle-emitting molecular radionuclide therapies is rising, however clinical translation of Auger electron-emitting radionuclides is hampered by uncertainty around their exact subcellular localisation, which in turn affects the accuracy of dosimetry. This review aims to discuss and compare the advantages and disadvantages of various subcellular localisation methods available to localise radiopharmaceuticals and radionuclides for in vitro investigations.
KW - Ion beam
KW - Laser ablation
KW - Microautoradiography
KW - Radionuclide
KW - Subcellular localisation
KW - X-ray fluorescence microscopy
UR - http://www.scopus.com/inward/record.url?scp=85105286100&partnerID=8YFLogxK
U2 - 10.1016/j.nucmedbio.2021.03.010
DO - 10.1016/j.nucmedbio.2021.03.010
M3 - Review article
AN - SCOPUS:85105286100
SN - 0969-8051
VL - 98-99
SP - 18
EP - 29
JO - Nuclear Medicine and Biology
JF - Nuclear Medicine and Biology
ER -
